• Clinical Evidence

Taking Control of Hyperglycemia to Improve Patient Care: How One Hospital Resolved a Low Benchmark Indicator and Became a Best Practice Site Through Use of EndoTool Glycemic Control Software

Setting: 71-bed full-service community hospital

Objective

This study compares glycemic outcomes before and after implementation of glycemic control software (EndoTool) for patients receiving intravenous insulin, all of whom were previously treated using a paper algorithm.

Setting

71-bed full-service community hospital.

Results

  • Incidence of hypoglycemia <70 mg/dL decreased 80% with EndoTool, from 4% to 0.8% of blood glucose readings.
  • Incidence of hyperglycemia >200 mg/dL decreased 53.8% with EndoTool, from 26% to 12% of blood glucose readings.
  • Mean glucose housewide decreased 21.7 mg/dL with EndoTool, from 183.9 to 162.2 mg/dL, while mean glucose within intensive care units decreased 20.1 mg/dL with EndoTool, from 184.1 to 147.1 mg/dL, achieving top performer status in the Remote Automated Laboratory System (RAL) benchmarking program.
  • Average time to achieve two consecutive blood glucose readings <150 mg/dL was 4.8 hours with EndoTool.
  • Average length of stay for DKA patients decreased from 3.3 to 2.66 days with EndoTool, representing an estimated $3,615.16 cost savings per patient and $74,932.41 cost savings per year.

Conclusions

Use of glycemic control software (EndoTool) allows better and more rapid glucose control than a paper algorithm and, according to physicians and nurses, makes transitioning from intravenous to subcutaneous insulin much easier.
Objective

This study compares glycemic outcomes before and after implementation of glycemic control software (EndoTool) for patients receiving intravenous insulin, all of whom were previously treated using a paper algorithm.

Setting

71-bed full-service community hospital.

Results
  • Incidence of hypoglycemia <70 mg/dL decreased 80% with EndoTool, from 4% to 0.8% of blood glucose readings.
  • Incidence of hyperglycemia >200 mg/dL decreased 53.8% with EndoTool, from 26% to 12% of blood glucose readings.
  • Mean glucose housewide decreased 21.7 mg/dL with EndoTool, from 183.9 to 162.2 mg/dL, while mean glucose within intensive care units decreased 20.1 mg/dL with EndoTool, from 184.1 to 147.1 mg/dL, achieving top performer status in the Remote Automated Laboratory System (RAL) benchmarking program.
  • Average time to achieve two consecutive blood glucose readings <150 mg/dL was 4.8 hours with EndoTool.
  • Average length of stay for DKA patients decreased from 3.3 to 2.66 days with EndoTool, representing an estimated $3,615.16 cost savings per patient and $74,932.41 cost savings per year.
Conclusions

Use of glycemic control software (EndoTool) allows better and more rapid glucose control than a paper algorithm and, according to physicians and nurses, makes transitioning from intravenous to subcutaneous insulin much easier.

References

Authors

Sondra Boecker, RN, CDE; Linda Barhorst, BSN, CDE.

Source

Presented at EndoTool® User Group Meeting.

Year

2013

Quick navigation
Objective
Setting
Results
Conclusions
References
Objective

This study compares glycemic outcomes before and after implementation of glycemic control software (EndoTool) for patients receiving intravenous insulin, all of whom were previously treated using a paper algorithm.

Setting

71-bed full-service community hospital.

Results
  • Incidence of hypoglycemia <70 mg/dL decreased 80% with EndoTool, from 4% to 0.8% of blood glucose readings.
  • Incidence of hyperglycemia >200 mg/dL decreased 53.8% with EndoTool, from 26% to 12% of blood glucose readings.
  • Mean glucose housewide decreased 21.7 mg/dL with EndoTool, from 183.9 to 162.2 mg/dL, while mean glucose within intensive care units decreased 20.1 mg/dL with EndoTool, from 184.1 to 147.1 mg/dL, achieving top performer status in the Remote Automated Laboratory System (RAL) benchmarking program.
  • Average time to achieve two consecutive blood glucose readings <150 mg/dL was 4.8 hours with EndoTool.
  • Average length of stay for DKA patients decreased from 3.3 to 2.66 days with EndoTool, representing an estimated $3,615.16 cost savings per patient and $74,932.41 cost savings per year.
Conclusions

Use of glycemic control software (EndoTool) allows better and more rapid glucose control than a paper algorithm and, according to physicians and nurses, makes transitioning from intravenous to subcutaneous insulin much easier.

References

Authors

Sondra Boecker, RN, CDE; Linda Barhorst, BSN, CDE.

Source

Presented at EndoTool® User Group Meeting.

Year

2013

Short and Sweet Headlines are Best!

Related posts

Image
  • Clinical Evidence

Near Elimination of Severe Hypoglycemia with EndoTool IV Across a 19-Hospital Health System

Near Elimination of Severe Hypoglycemia with EndoTool IV Across a 19-Hospital Health System

To evaluate the impact of EndoTool IV insulin dosing software on reducing severe hypoglycemia (SH) (blood glucose < 40 mg/dL) across 19-hospitals at a prominent health system, including outcomes in patients with renal insufficiency.
Image
  • Clinical Evidence

Temple Health Achieves Zero Severe Hypoglycemia in Renally Impaired Patients with EndoTool SubQ

Temple Health Achieves Zero Severe Hypoglycemia in Renally Impaired Patients with EndoTool SubQ

To evaluate the safety and efficacy of the EndoTool SubQ (ETSQ) insulin dosing application for subcutaneous (SQ) insulin administration in hospitalized patients, and to compare clinical outcomes against those treated using a standard insulin order set. The analysis also examined performance in high-risk patients with advanced renal impairment.
Image
  • Clinical Evidence

Improving Inpatient Glycemic Safety at Temple Health with EndoTool SubQ

Improving Inpatient Glycemic Safety at Temple Health with EndoTool SubQ

Temple Health, a 3-hospital academic system was experiencing high rates of hypoglycemia due to reliance on sliding scale insulin (SSI). To improve safety and align with ADA guidelines, the hospital implemented EndoTool SubQ, a patient-specific insulin dosing software the supports four dosing protocols, including basal-bolus-correction (BBC).
Get in Touch

Ready to get started?

Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*
By submitting this form, you consent to the processing of your personal information, including sensitive personal information you provide, in accordance with the Monarch Medical Technologies Privacy Notice.